To investigate mortality and hospitalization outcomes associated with medication misadventure (including medication errors [MEs], such as the use of potentially inappropriate medications [PIMs], and adverse drug events [ADEs]) among people with cognitive impairment or dementia.
Data Sources:
Ovid MEDLINE, Ovid EMBASE, Ovid International Pharmaceutical Abstracts, Cumulative Index to Nursing and Allied Health Literature, and Cochrane Central Register of Controlled Trials were searched from inception to December 2019.
Study Selection and Data Extraction:
Relevant studies using any study design were included. Reviewers independently performed critical appraisal and extracted relevant data.
Data Synthesis:
The systematic review included 10 studies that reported the outcomes of mortality or hospitalization associated with medication misadventure, including PIMs (n=5), ADEs (n=2), a combination of MEs and ADEs (n=2), and drug interactions (n=1). Five studies examining the association between PIMs and mortality/hospitalization were included in the meta-analyses. Exposure to PIMs was not associated with either mortality (odds ratio [OR]=1.36; 95%CI=0.79-2.35) or hospitalization (OR=1.02; 95%CI=0.83-1.26). In contrast, single studies indicated that ADEs with cholinesterase inhibitors were associated with mortality and hospitalization.
Relevance to Patient Care and Clinical Practice:
Individuals with cognitive impairment or dementia are at increased risk of medication misadventure; based on relatively limited published data, this does not necessarily translate to increased mortality and hospitalization.
Conclusions:
Overall, medication misadventure was not associated with mortality or hospitalization in people with cognitive impairment or dementia, noting the limited number of studies, difficulty in controlling potential confounding variables, and that most studies focus on PIMs.
CochraneZRHeinDGregoryPJ. Medication misadventures I: adverse drug reactions. In: MalonePMKierKLStanovichJEMaloneMJ, eds. Drug Information: A Guide for Pharmacists. 5th ed.McGraw-Hill; 2013:chap 15.
2.
RougheadLSempleSRosenfeldE. Literature Review: Medication Safety in Australia. Australian Commission on Safety and Quality in Health Care; 2013.
3.
BrennanTALeapeLLLairdNM, et al. Incidence of adverse events and negligence in hospitalized patients: results of the Harvard Medical Practice Study I. 1991. Qual Saf Health Care. 2004;13:145-151; discussion 151-152.
4.
DonaldsonLJKelleyETDhingra-KumarNKienyMPSheikhA. Medication without harm: WHO’s third global patient safety challenge. Lancet. 2017;389:1680-1681.
5.
KaboliPJGlasgowJMJaipaulCK, et al. Identifying medication misadventures: poor agreement among medical record, physician, nurse, and patient reports. Pharmacotherapy. 2010;30:529-538.
LimRHSharmeenT. Medicines management issues in dementia and coping strategies used by people living with dementia and family carers: a systematic review. Int J Geriatr Psychiatry. 2018;33:1562-1581.
14.
RuscinJMSemlaTP. Assessment of medication management skills in older outpatients. Ann Pharmacother. 1996;30:1083-1088.
15.
SunderlandTTariotPNNewhousePA. Differential responsivity of mood, behavior, and cognition to cholinergic agents in elderly neuropsychiatric populations. Brain Res. 1988;472:371-389.
16.
WalshKAO’RiordanDKearneyPMTimmonsSByrneS. Improving the appropriateness of prescribing in older patients: a systematic review and meta-analysis of pharmacists’ interventions in secondary care. Age Ageing. 2016;45:201-209.
17.
ReeveETrenamanSCRockwoodKHilmerSN. Pharmacokinetic and pharmacodynamic alterations in older people with dementia. Expert Opin Drug Metab Toxicol. 2017;13:651-668.
18.
SillaireARBreuilhLSalleronJ, et al. Reasons that prevent the inclusion of Alzheimer’s disease patients in clinical trials. Br J Clin Pharmacol. 2013;75:1089-1097.
19.
NairNPChalmersLConnollyM, et al. Prediction of hospitalization due to adverse drug reactions in elderly community-dwelling patients (The PADR-EC Score). PLoS One. 2016;11:e0165757.
20.
KanagaratnamLDrameMTrenqueT, et al. Adverse drug reactions in elderly patients with cognitive disorders: a systematic review. Maturitas. 2016;85:56-63.
21.
XingXZhuCLiangY, et al. Associations between potentially inappropriate medications and adverse health outcomes in the elderly: a systematic review and meta-analysis. Ann Pharmacother. 2019;53:1005-1019.
22.
EshetieTCNguyenTAGillamMHEllettLMK. A narrative review of problems with medicines use in people with dementia. Expert Opin Drug Saf. 2018;17:825-836.
23.
MoherDLiberatiATetzlaffJAltmanDG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med. 2009;151:264-269.
24.
Ackroyd-StolarzSHartnellNMackinnonNJ. Demystifying medication safety: making sense of the terminology. Res Social Adm Pharm. 2006;2:280-289.
25.
MorrisJNFriesBEMehrDR, et al. MDS Cognitive Performance Scale. J Gerontol. 1994;49:M174-M182.
26.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. American Psychiatric Association; 2013.
27.
BlackburnHLBentonAL. Revised administration and scoring of the digit span test. J Consult Psychol. 1957;21:139-143.
28.
HirschJANicolaGMcGintyG, et al. ICD-10: history and context. AJNR Am J Neuroradiol. 2016;37:596-599.
29.
FolsteinMFFolsteinSEMcHughPR. “Mini-mental state”: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189-198.
MatsudaOSaitoMKatoMAzamiHShidoE. Wechsler Adult Intelligence Scale-III profile in the early stages of Alzheimer’s disease: performance in subtests sensitive to and resistant to normal decline with ageing. Psychogeriatrics. 2015;15:1-6.
32.
American Geriatrics Society 2015 Beers Criteria Update Expert Panel. American Geriatrics Society 2015 updated Beers criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2015;63:2227-2246.
33.
GallagherPRyanCByrneSKennedyJO’MahonyD. STOPP (Screening Tool of Older Person’s Prescriptions) and START (Screening Tool to Alert doctors to Right Treatment): consensus validation. Int J Clin Pharmacol Ther. 2008;46:72-83.
34.
Renom-GuiterasAMeyerGThurmannPA. The EU(7)-PIM list: a list of potentially inappropriate medications for older people consented by experts from seven European countries. Eur J Clin Pharmacol. 2015;71:861-875.
35.
WamilNMattssonSGustafssonM. Assessment of potentially inappropriate medications using the EU (7)-PIM list and the Swedish quality indicators. Int J Clin Pharm. 2019;41:903-912.
36.
WittichCMBurkleCMLanierWL. Medication errors: an overview for clinicians. Mayo Clin Proc. 2014;89:1116-1125.
HigginsJPGreenS. Cochrane Handbook for Systematic Reviews of Interventions. Vol 4. John Wiley & Sons; 2011.
45.
SköldungerAFastbomJWimoAFratiglioniLJohnellK. Impact of inappropriate drug use on hospitalizations, mortality, and costs in older persons and persons with dementia: findings from the SNAC study. Drugs Aging. 2015;32:671-678.
46.
Renom-GuiterasAThurmannPAMirallesR, et al. Potentially inappropriate medication among people with dementia in eight European countries. Age Ageing. 2018;47:68-74.
47.
RaivioMMLaurilaJVStrandbergTETilvisRSPitkäläKH. Use of inappropriate medications and their prognostic significance among in-hospital and nursing home patients with and without dementia in Finland. Drugs Aging. 2006;23:333-343.
48.
PorterBArthurASavvaGM. How do potentially inappropriate medications and polypharmacy affect mortality in frail and non-frail cognitively impaired older adults? A cohort study. BMJ Open. 2019;9:e026171.
49.
CrossAJGeorgeJWoodwardMC, et al. Potentially inappropriate medication, anticholinergic burden, and mortality in people attending memory clinics. J Alzheimers Dis. 2017;60:349-358.
50.
MullanJBurnsPMohananLLagoLJordanMPotterJ. Hospitalisation for medication misadventures among older adults with and without dementia: a 5-year retrospective study. Australas J Ageing. 2019;38:e135-e141.
51.
FrancoisMSicsicJPelletier FleuryN. Drugs for dementia and excess of hospitalization: a longitudinal French study. J Alzheimers Dis. 2018;61:1627-1637.
52.
LiperotiRSgangaFLandiF, et al. Antipsychotic drug interactions and mortality among nursing home residents with cognitive impairment. J Clin Psychiatry. 2017;78:e76-e82.
53.
GustafssonMSjölanderMPfisterBJonssonJSchneedeJLövheimH. Drug-related hospital admissions among old people with dementia. Eur J Clin Pharmacol. 2016;72:1143-1153.
54.
CipolleRStrandLMorleyP. Pharmaceutical Care Practice: The Patient-Centered Approach to Medication Management Services. McGraw-Hill Health Professions Division; 1998.
55.
AliTBSchleretTRReillyBMChenWYAbagyanR. Adverse effects of cholinesterase inhibitors in dementia, according to the pharmacovigilance databases of the United-States and Canada. PLoS One. 2015;10:e0144337.
56.
JohnellK. Inappropriate drug use in people with cognitive impairment and dementia: a systematic review. Curr Clin Pharmacol. 2015;10:178-184.
57.
FortinskyRHZlatevaIDelaneyCKleppingerA. Primary care physicians’ dementia care practices: evidence of geographic variation. Gerontologist. 2010;50:179-191.
58.
LeikolaSDimitrowMLylesAPitkäläKAiraksinenM. Potentially inappropriate medication use among Finnish non-institutionalized people aged ≥65 years: a register-based, cross-sectional, national study. Drugs Aging. 2011;28:227-236.
59.
HukinsDMacleodUBolandJW. Identifying potentially inappropriate prescribing in older people with dementia: a systematic review. Eur J Clin Pharmacol. 2019;75:467-481.
60.
VetranoDLTosatoMCollocaG, et al. Polypharmacy in nursing home residents with severe cognitive impairment: results from the SHELTER study. Alzheimers Dement. 2013;9:587-593.
61.
ParsonsCJohnstonSMathieE, et al. Potentially inappropriate prescribing in older people with dementia in care homes: a retrospective analysis. Drugs Aging. 2012;29:143-155.
62.
MorinLLarocheMTexierGJohnellK. Prevalence of potentially inappropriate medication use in older adults living in nursing homes: a systematic review. J Am Med Dir Assoc. 2016;17:862.e1-e9.
63.
AlznerRBauerUPitzerSSchreierMMOsterbrinkJIglsederB. Polypharmacy, potentially inappropriate medication and cognitive status in Austrian nursing home residents: results from the OSiA study. Wien Med Wochenschr. 2016;166:161-165.
64.
BosboomPRAlfonsoHAlmeidaOPBeerC. Use of potentially harmful medications and health-related quality of life among people with dementia living in residential aged care facilities. Dement Geriatr Cogn Dis Extra. 2012;2:361-371.
65.
LauDTMercaldoNDHarrisATTrittschuhEShegaJWeintraubS. Polypharmacy and potentially inappropriate medication use among community-dwelling elders with dementia. Alzheimer Dis Assoc Disord. 2010;24:56.
66.
FitzgeraldSPBeanNG. An analysis of the interactions between individual comorbidities and their treatments—implications for guidelines and polypharmacy. J Am Med Dir Assoc. 2010;11:475-484.
67.
SmithDLovellJWellerC, et al. A systematic review of medication non-adherence in persons with dementia or cognitive impairment. PLoS One. 2017;12:e0170651.
68.
SönnerstamESjölanderMGustafssonM. An evaluation of the prevalence of potentially inappropriate medications in older people with cognitive impairment living in Northern Sweden using the EU (7)-PIM list. Eur J Clin Pharmacol. 2017;73:735-742.
69.
LiewTMLeeCSShawnKLGChangZY. Potentially inappropriate prescribing among older persons: a meta-analysis of observational studies. Ann Fam Med. 2019;17:257-266.
70.
WangPWangQLiFBianMYangK. Relationship between potentially inappropriate medications and the risk of hospital readmission and death in hospitalized older patients. Clin Interv Aging. 2019;14:1871-1878.
71.
PorterB. Understanding Multiple Medication Use in People With Dementia: A Pharmacoepidemiology Study of Prevalence, Intervention and Associated Harms. Thesis. University of East Anglia; 2019.
72.
FerreiraFValéJSFreitasMPDCamargosEFKusanoLTESantos-NetoLLd. Potential high-risk drug-drug interactions among elderly outpatients with dementia: a cross-sectional study. Geriatr Gerontol Aging. 2015;9:21-25.
73.
KazmierskiJMessini-ZachouCGkiokaMTsolakiM. The impact of a long-term rivastigmine and donepezil treatment on all-cause mortality in patients with Alzheimer’s disease. Am J Alzheimers Dis Other Demen. 2018;33:385-393.
74.
LauDTKasperJDPotterDLylesABennettRG. Hospitalization and death associated with potentially inappropriate medication prescriptions among elderly nursing home residents. Arch Intern Med. 2005;165:68-74.
75.
KlarinIWimoAFastbomJ. The association of inappropriate drug use with hospitalisation and mortality: a population-based study of the very old. Drugs Aging. 2005;22:69-82.
76.
RuggieroCDell’AquilaGGasperiniB, et al. Potentially inappropriate drug prescriptions and risk of hospitalization among older, Italian, nursing home residents. Drugs Aging. 2010;27:747-758.
77.
MuellerCMolokhiaMPereraG, et al. Polypharmacy in people with dementia: associations with adverse health outcomes. Exp Gerontol. 2018;106:240-245.
78.
EllettLMKPrattNLRamsayENBarrattJDRougheadEE. Multiple anticholinergic medication use and risk of hospital admission for confusion or dementia. J Am Geriatr Soc. 2014;62:1916-1922.
79.
Sevilla-SánchezDMolist-BrunetNAmblàs-NovellasJEspaulella-PanicotJCodina-JanéC. Potentially inappropriate medication at hospital admission in patients with palliative care needs. Int J Clin Pharm. 2017;39:1018-1030.
80.
InglisF. The tolerability and safety of cholinesterase inhibitors in the treatment of dementia. Int J Clin Pract Suppl. 2002;(127):45-63.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
